Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb:40 Suppl 1:109-115.
doi: 10.1111/liv.14345.

Optimizing curative management of hepatocellular carcinoma

Pierre Nahon  1   2   3 , Eric Vibert  4 , Jean-Charles Nault  1   2   3 , Nathalie Ganne-Carrié  1   2   3 , Marianne Ziol  2   3   5 , Olivier Seror  2   3   6
Affiliations
Review

Optimizing curative management of hepatocellular carcinoma

Pierre Nahon et al. Liver Int. 2020 Feb.

Abstract

The goal of curative management of hepatocellular carcinoma is to provide the best chance of remission. However, recurrence rates for both local and distant relapse are high. Patient subgroups at higher risk of these events can be identified based on histological patterns that are closely linked to specific molecular subtypes. Patient outcome has improved with more effective therapeutic strategies thanks to technological advances in surgical techniques and percutaneous ablation. The main goal of controlling the cause of liver disease is to decrease distant/late recurrence and prevent deterioration of hepatic function. Ongoing trials testing the combination of neoadjuvant and/or adjuvant regimens with these procedures as well as routine tumour molecular analysis may modify therapeutic algorithms for hepatocellular carcinoma in the future.

Keywords: ablation; adjuvant; biopsy sample; hepatocellular carcinoma; resection.

PubMed Disclaimer

References

REFERENCES

    1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236.
    1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301-1314.
    1. Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450-1462.
    1. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200-207.
    1. Nault J-C, Sutter O, Nahon P, Ganne-Carrié N, Séror O. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. J Hepatol. 2018;68:783-797.

LinkOut - more resources